

IBD Prognostic Biomarker Results
Report generated: DD/MM/YYYY HH:MM

Anonymised patient information

ID 1:
ID 2:
Sex:
Age:
Diagnosis:
Comorbidities:
Prior treatment:
Smoker status:

Tested at Clinical Genetics Laboratory
Level 6, Addenbrooke's Treatment Centre,
Cambridge University Hospitals
NHS Foundation Trust
Hills Road, Cambridge CB2 0QQ
Lab Accreditation Number: xxxx

Sample information

Clinician name:
GMC/Doctor#:
Hospital/Account Name:
Date of Sample Collection:

Results **HIGH RISK**

- There is **95% confidence that this patient is in the high-risk subgroup.**
- Patients in the high-risk group are more likely to experience an aggressive disease course.
- This is characterised by shorter time to first treatment escalation, and increased risk of multiple treatment escalations.


Test Description

PredictSURE IBD™ is a 17-gene* qPCR-based prognostic test with a proprietary algorithm that stratifies inflammatory bowel disease (IBD) patients into high and low-risk groups at the point of diagnosis. The test has been validated in both Crohn's disease and ulcerative colitis. High-risk patients are more likely to experience significantly more aggressive disease than low-risk patients, with need for earlier and more frequent treatment escalations over time. Contact info@predictimmune.com for further information.

Probability of risk classification

Figure 1. Frequency distribution of risk scores for a representative IBD population of ~200 patients, illustrating the proportion of patients at each risk score.

For this patient, the assigned risk classification (and risk score) is indicated by a vertical solid arrow.



The risk score is translated into a confidence of risk group allocation. A risk score of 0.88 translates to an 88% confidence of being in the high-risk subgroup. A risk score of 0.15 translates to an 85% (100% - 15%) confidence of being in the low-risk subgroup.

Signed

Prof./Dr. first name, last name, qualification

Date

Testing Details

Product code P5854, consisting of
Reagent kit (PI001) lot #:
Quality control kit (PI002) lot #:
Analysis date/time:
Software version:
QC result:

FOR IN VITRO DIAGNOSTIC USE ONLY. The PredictSURE IBD™ prognostic test has been developed by Predictimmune Ltd, UK for prognostication purposes. The test was developed on newly diagnosed, treatment naïve IBD patients (55% Crohn's disease; 45% ulcerative colitis). It is not intended to be used to predict patient response to individual treatments. The testing laboratory is responsible for executing the test and reporting the patient-specific results. Predictimmune Ltd retain responsibility for the development of the test and performance of the test under conditions defined in the test IFU. *Inf: LOC730227, NUDT7, P2RY14, IL18RAP, GZMH, IFI44L, GBP5, FCRL5, LY96, HP, VTRNA1-1, TRGC2/TARP, LGALS1, GZMK, TRGV3. Ref: CDV3, 18S